56
Participants
Start Date
January 31, 1998
Primary Completion Date
September 30, 2010
Study Completion Date
September 30, 2010
zuclopenthixol
Patients will be administered zuclopenthixol orally in doses between 4 -24 mg/day, depending on an effective reduction of symptoms
risperidone
Patients will be administered risperidone orally in doses between 1-6 mg/day, depending on an effective reduction of symptoms
Neurobiology Research Unit, University of Copenhagen, Rigshospitalet, Copenhagen
Dept. of Nuclear Medicine, University of Copenhagen, Bispebjerg Hospital, Copenhagen NV
University of Copenhagen, Dept. F, Bispebjerg Hospital, Copenhagen NV
University of Copenhagen, Dept. of Psychiatry E, Bispebjerg Hospital, Copenhagen NV
Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup, Glostrup Municipality
Danish Research Center for Magnetic Resonance Imaging, Hvidovre Hospital, Hvidovre
Collaborators (1)
University of Copenhagen
OTHER
Glostrup University Hospital, Copenhagen
OTHER
Rigshospitalet, Denmark
OTHER
Hvidovre University Hospital
OTHER
The Danish Medical Research Council
OTHER
Copenhagen Hospital Corporation
OTHER
Janssen-Cilag Ltd.
INDUSTRY
The Novo Nordic Foundation
OTHER
Birte Glenthoj
OTHER